Beta Drugs (NSE:BETA) DeferredTaxAndRevenue: ₹0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BETA Beta Drugs Ltd NSE:BETA
94 GF Score
Price ₹2,229.10
GF Value ₹1,982.44
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Beta Drugs DeferredTaxAndRevenue?

Beta Drugs NSE:BETA -1.40% 94 DeferredTaxAndRevenue is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:BETA with a GF Score™ of 94/100 and a GF Value™ of ₹1,982.44 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Beta Drugs's current deferred tax and revenue for the quarter that ended in Mar. 2026 was ₹0 Mil.

Beta Drugs DeferredTaxAndRevenue Related Terms

Beta Drugs DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Beta Drugs's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Drugs DeferredTaxAndRevenue Chart

Beta Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Beta Drugs Quarterly Data
Mar17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:BETA
94GF Score
Beta Drugs Ltd NSE:BETA
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of ₹0 Mil mean?
Beta Drugs (NSE:BETA) has a DeferredTaxAndRevenue of ₹0 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Beta Drugs.
Is Beta Drugs' DeferredTaxAndRevenue too high?
Beta Drugs' current DeferredTaxAndRevenue is ₹0 Mil. Overall, Beta Drugs has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' DeferredTaxAndRevenue compare to ZTS and UTHR?
Beta Drugs' DeferredTaxAndRevenue of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Drug Manufacturers company?
A good DeferredTaxAndRevenue depends on the Drug Manufacturers industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Beta Drugs. Beta Drugs's current DeferredTaxAndRevenue is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,982.44, compared to a current price of ₹2,229.10 — trading 12.4% above its estimated fair value. The current DeferredTaxAndRevenue is ₹0 Mil. Beta Drugs' overall GF Score™ is 94/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current DeferredTaxAndRevenue is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beta Drugs (NSE:BETA) Overvalued in 2026?

Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued. The current stock price of ₹2,229.10 is trading 12.4% above its estimated GF Value™ of ₹1,982.44. GuruFocus considers Beta Drugs to be Modestly Overvalued.

Key valuation signals for NSE:BETA:

  • DeferredTaxAndRevenue: ₹0 Mil
  • GF Value™: ₹1,982.44 vs. price of ₹2,229.10 (12.4% above fair value)
  • GF Score™: 94/100 with 7 warning signs

No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beta Drugs Business Description

Address SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
94GF Score

Get the complete analysis for NSE:BETA

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,229.10
Price
₹1,982.44
GF Value